![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EID1 |
Gene summary for EID1 |
![]() |
Gene information | Species | Human | Gene symbol | EID1 | Gene ID | 23741 |
Gene name | EP300 interacting inhibitor of differentiation 1 | |
Gene Alias | C15orf3 | |
Cytomap | 15q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9Y6B2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23741 | EID1 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 1.33e-02 | 6.67e-01 | 0.1622 |
23741 | EID1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 3.13e-05 | 3.31e-01 | 0.1575 |
23741 | EID1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 6.83e-13 | 3.48e-01 | 0.1545 |
23741 | EID1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 7.18e-05 | 1.62e-01 | 0.1569 |
23741 | EID1 | P1_S1_AK | Human | Skin | AK | 1.63e-17 | -5.79e-01 | -0.3399 |
23741 | EID1 | P2_S3_AK | Human | Skin | AK | 5.85e-09 | -4.76e-01 | -0.3287 |
23741 | EID1 | P2_S4_SCCIS | Human | Skin | SCCIS | 2.47e-12 | -6.56e-01 | -0.3043 |
23741 | EID1 | P3_S6_AK | Human | Skin | AK | 6.95e-08 | -6.24e-01 | -0.3256 |
23741 | EID1 | P4_S8_cSCC | Human | Skin | cSCC | 1.05e-18 | -4.30e-01 | -0.3095 |
23741 | EID1 | P5_S10_cSCC | Human | Skin | cSCC | 1.41e-26 | -5.66e-01 | -0.299 |
23741 | EID1 | P1_cSCC | Human | Skin | cSCC | 5.13e-24 | 1.10e+00 | 0.0292 |
23741 | EID1 | P2_cSCC | Human | Skin | cSCC | 1.52e-15 | 6.80e-01 | -0.024 |
23741 | EID1 | P4_cSCC | Human | Skin | cSCC | 5.60e-12 | 7.03e-01 | -0.00290000000000005 |
23741 | EID1 | P10_cSCC | Human | Skin | cSCC | 2.06e-36 | 1.59e+00 | 0.1017 |
23741 | EID1 | cSCC_p1 | Human | Skin | cSCC | 1.49e-06 | -2.26e-01 | -0.1916 |
23741 | EID1 | cSCC_p10 | Human | Skin | cSCC | 3.23e-05 | -3.84e-01 | -0.2095 |
23741 | EID1 | cSCC_p11 | Human | Skin | cSCC | 1.58e-10 | -4.69e-01 | -0.2102 |
23741 | EID1 | cSCC_p3 | Human | Skin | cSCC | 4.08e-09 | -6.25e-01 | -0.2085 |
23741 | EID1 | cSCC_p4 | Human | Skin | cSCC | 8.13e-21 | -5.79e-01 | -0.2022 |
23741 | EID1 | cSCC_p6 | Human | Skin | cSCC | 1.45e-09 | -5.69e-01 | -0.1989 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
GO:00182054 | Cervix | CC | peptidyl-lysine modification | 62/2311 | 376/18723 | 1.04e-02 | 4.97e-02 | 62 |
GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
GO:00310561 | Colorectum | SER | regulation of histone modification | 37/2897 | 152/18723 | 2.80e-03 | 2.50e-02 | 37 |
GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
GO:00310562 | Colorectum | MSS | regulation of histone modification | 41/3467 | 152/18723 | 6.41e-03 | 4.27e-02 | 41 |
GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
GO:20007564 | Esophagus | ESCC | regulation of peptidyl-lysine acetylation | 43/8552 | 63/18723 | 2.43e-04 | 1.50e-03 | 43 |
GO:19019835 | Esophagus | ESCC | regulation of protein acetylation | 49/8552 | 77/18723 | 1.12e-03 | 5.60e-03 | 49 |
GO:00350653 | Esophagus | ESCC | regulation of histone acetylation | 36/8552 | 54/18723 | 1.49e-03 | 7.06e-03 | 36 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EID1 | SNV | Missense_Mutation | novel | c.313T>A | p.Trp105Arg | p.W105R | Q9Y6B2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EID1 | insertion | Frame_Shift_Ins | novel | c.382_383insATATGTA | p.Leu128HisfsTer4 | p.L128Hfs*4 | Q9Y6B2 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
EID1 | SNV | Missense_Mutation | novel | c.41N>A | p.Ser14Asn | p.S14N | Q9Y6B2 | protein_coding | tolerated(0.06) | benign(0.181) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
EID1 | SNV | Missense_Mutation | c.143G>A | p.Gly48Glu | p.G48E | Q9Y6B2 | protein_coding | tolerated(0.41) | benign(0.056) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
EID1 | SNV | Missense_Mutation | c.300G>T | p.Glu100Asp | p.E100D | Q9Y6B2 | protein_coding | tolerated(0.16) | benign(0.019) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EID1 | SNV | Missense_Mutation | novel | c.101N>A | p.Gly34Asp | p.G34D | Q9Y6B2 | protein_coding | deleterious(0.01) | possibly_damaging(0.708) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
EID1 | SNV | Missense_Mutation | novel | c.459N>T | p.Lys153Asn | p.K153N | Q9Y6B2 | protein_coding | tolerated(0.15) | probably_damaging(0.998) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EID1 | SNV | Missense_Mutation | c.157G>A | p.Glu53Lys | p.E53K | Q9Y6B2 | protein_coding | tolerated(0.76) | possibly_damaging(0.776) | TCGA-D1-A16F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EID1 | SNV | Missense_Mutation | rs374971624 | c.217C>T | p.Arg73Trp | p.R73W | Q9Y6B2 | protein_coding | tolerated(0.09) | benign(0.335) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
EID1 | SNV | Missense_Mutation | c.464N>T | p.Pro155Leu | p.P155L | Q9Y6B2 | protein_coding | tolerated(0.46) | probably_damaging(0.998) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |